Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.74 |
| ▸ | RAF1 | P04049 | 5/20 | 0.74 |
| ▸ | EGFR | P00533 | 6/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.64 |
| ▸ | SRC | P12931 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970665 | 0.89 | MAP2K1 (0.73) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14116902 | 0.88 | MAP2K1 (0.71) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14116905 | 0.88 | MAP2K1 (0.68) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14595247 | 0.87 | MAP2K1 (0.69) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14116952 | 0.87 | MAP2K1 (0.75) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14595250 | 0.86 | MAP2K1 (0.61) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL6382750 | 0.85 | MAP2K1 (1.00) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL4954951 | 0.85 | MAP2K1 (0.76) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL4954921 | 0.85 | MAP2K1 (0.73) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL14116955 | 0.84 | MAP2K1 (0.72) | MAP2K1RAF1EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-7067532-B2 | Substituted quinolines as antitumor agents | ASTRAZENECA (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | disclosed |
| EP-1337524-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002044166-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | MAP2K1 4027/4885RAF1 1565/4885EGFR 260/4885 |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | NQO2, NQO1, TP53 | MAP2K1 4209/4885RAF1 743/4885EGFR 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.